.Though Alkeus Pharmaceuticals’ oral eye ailment asset fell short to dramatically lower geographic degeneration (GA) lesion development, the biotech is citing “medically meaningful” outcomes and
Read moreDespite blended market, a financial backing resurgence could be being available in Europe: PitchBook
.While the biotech financial investment performance in Europe has actually slowed rather observing a COVID-19 backing boom in 2021, a brand-new report coming from PitchBook
Read moreDaiichi pays for Merck $170M to develop lung cancer cells T-cell engager treaty
.Merck & Co. has actually quickly made back a few of the costs of its Harpoon Therapeutics purchase, drawing in $170 thousand in advance through
Read moreCullinan, after $25M bargain, hands back bispecific to Port
.Cullinan Rehab was actually made an impression on sufficient with Harbour BioMed’s bispecific invulnerable reactor that it gave up $25 million in 2013 for the
Read moreCue Biopharma queues up J&J veterinarian as CBO– Chutes & Ladders
.Accept to today’s Chutes & Ladders, our roundup of substantial leadership hirings, shootings as well as retirings throughout the field. Please deliver the praise– or
Read moreCompass delays period 3 psychedelic information, gives up 30% of workers
.Compass Pathways’ adventure to period 3 psychedelic clinical depression records is taking much longer than counted on. Along with the trials swamping through months, the
Read moreCombo outcomes, Vicodin overlook and outstanding security
.Tip has reported phase 3 data on its near-approval discomfort medication candidate suzetrigine, shedding light on how the non-opioid pain reliever mixes along with advil
Read moreCognition’s period 2 radiate information stain Alzheimer’s possibility
.Knowledge Therapies’ period 2 sparkle test has actually taken a number of the gloss off the Alzheimer’s disease medication prospect CT1812. The oral sigma-2 opponent
Read moreChutes & Ladders– Gilead’s Merdad Parsey goes, Cassava loses CEO
.Invite to recently’s Chutes & Ladders, our summary of considerable leadership hirings, firings and also retirings around the industry. Please deliver the praise– or the
Read moreChinese the hormone insulin maker’s GLP-1 bests Ozempic in ph. 2
.Chinese insulin maker Gan & Lee Pharmaceuticals is actually wading into the obesity globe with an injectable GLP-1 agonist that hammered Novo Nordisk’s Ozempic (semaglutide)
Read more